The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Centese sales in the US from 2017 to 2023, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Centese Inc (Centese) is a medical device company that offers intelligent surgical drainage systems. Its post-operative surgical drainage system, Thoragaurd, provides reliable data to ICU teams to help the make informed decisions and streamline their labor intensive workflow. Centese’ Thoroguard’s chest tube design and control system facilitates automatic clearance of blood and fluid without clinical intervention from the chest tubes and drainage line. The company serves hospitals, medical practice centers, and healthcare sectors. Centese is headquartered in Omaha, Nebraska, the US.
The key metrics of Centese related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2023 are shown below:
As Centese is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Centese.
For a detailed understanding of the performance of Centese, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.